Condition: HIV/TB Coinfection · Sponsor: The HIV Netherlands Australia Thailand Research Collaboration
The overall aim of the project is to evaluate optimal DTG dose for the combined treatment of TB and HIV infections with RIF based anti-TB therapy. This Stage II trial will determine precisely the PK parameters of DTG in combination with RIF regimen in Thai HIV/TB co-infected patients. After the optimal dose of DTG has been found, it will be further tested in a larger Stage III trial to assess its safety, tolerability and efficacy when used with RIF based regimen.
This description comes directly from the study's public registry record.
June Ohata, BS · 6626523040 · juneohata4@gmail.com
Always discuss trial participation with your own doctor first.
| Klang Hospital | Bangkok, Bangkok, Thailand | Recruiting |
| Bhumibol Adulyadej Hospital | Bangkok, Bangkok, Thailand | Recruiting |
| Infectious Disease, Chulalongkorn University | Bangkok, Bangkok, Thailand | Recruiting |
| Infectious Disease Taksin Hospital | Bangkok, Bangkok, Thailand | Recruiting |
| Infectious Disease Chonburi Hospital | Chon Buri, Changwat Chon Buri, Thailand | Recruiting |
| Bamrasnaradura Infectious Diseases Institute | Nonthaburi, Changwat Nonthaburi, Thailand | Recruiting |
| Infectious Disease Buddhachinaraj Phitsanulok Hospital | Phitsanulok, Changwat Phitsanulok, Thailand | Recruiting |
| Infectious Disease Chiangrai Prachanukroh Hospital | Chiang Rai, Chiangrai, Thailand | Recruiting |
| Chest Division, Faculty of Medicine, Chulalongkorn University | Bangkok, Thailand | Recruiting |
| HIV-NAT, Thai Red Cross - AIDS Research Centre | Bangkok, Thailand | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03731559